INVESTOR NARRATIVES FOR QUARTERLY REPORTS / FUNDING ROUNDS
120
OVER
YEARS
At iWisdom, we specialize in crafting data-driven investor narratives to build and maintain confidence throughout asset lifecycles. Our disciplined approach ensures alignment across key functions, helping optimize value and decision-making for commercial, medical, and R&D stakeholders.
OUR PRODUCTS
Future
State
Defining the ambition and designing a practical blueprint
Portfolio Prioritization
Portfolio
optimization
C-Suite
Governance
Governance design and operationalization
Investor
Ready
Build & maintain investor confidence throughout asset lifecycles
BUILD AND MAINTAIN INVESTOR CONFIDENCE THROUGHOUT ASSET LIFECYCLES
Create robust, data driven narratives for investors at predetermined timepoints and as needed.
STAKEHOLDERS
OPERATIONAL
MANAGEMENT
APPROACH
• Disciplined thinking and putting the discipline behind the numbers for valuation and ambition setting.
• 360 view of investor views / benchmark deals / constituents of value drivers.
• Activating value drivers to create an optimal sell / partner pitch with confidence.
• Setting the outcome / ambition upfront.
• Bringing in the understanding on pharmaceutical commercialization into the dynamics along with the network where / if relevant.
KEY OUTCOMES
• Setting the optimal ambition for the outcome.
• Confidence in the roadmap getting to that ambition – Both for the story & the external stakeholders.
• Advocacy within the investor network.
SOLUTIONS
• Stage gate Asset Planning Framework to streamline critical activities.
• Streamlining Governance boards across Commercial, R&D, setup and competitors.
• Investor-focused narratives prepared in advance and decision frameworks.
GOVERNANCE
Confidence by board that investors have the necessary information to meet their needs.
DECISION MAKING
Optimization of resources / valuation and ambition for go / no go in sell or partnerships.
FACILITATING SYNERGIES
All functions aligned on the optimal value for the asset and the subsequent investor narratives. Team able to pivot quickly in response to new evidence.
